Dynavax Technologies Corporation (DVAX)

Oncology Corporate Profile

Stock Performance

18.5300
-2.4500

HQ Location

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Company Description

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine.

Website: http://www.dynavax.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)MelanomaI
SD-101 (+ anti PD-1)toll-like receptor 9 (TLR9)Squamous cell cancer of the head and neck (SCCHN)I
SD-101 (+ anti IL-10)toll-like receptor 9 (TLR9)Various cancer typesIMerck
DV281toll-like receptor 9 (TLR9)Various cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.dynavax.com/

Recent News Headlines

Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting

3/20/2017 10:00 am

[Marketwired] - Dynavax Technologies Corporation announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 agonists at the 2017 American Association ...

Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update

3/13/2017 10:00 am

[Marketwired] - Dynavax Technologies Corporation today reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 ...

Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies

3/6/2017 01:00 pm

[Marketwired] - Dynavax Technologies Corporation announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's ...

Dynavax to Present at the Cowen and Company 37th Annual Health Care Conference

3/2/2017 11:00 am

[Marketwired] - Dynavax Technologies Corporation announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference next week in Boston, MA. The ...

Dynavax Announces FDA Acceptance for Review of Its Complete Response to November 2016 CRL and PDUFA Action Date for HEPLISAV-B(TM)

2/28/2017 09:00 pm

[Marketwired] - Dynavax Technologies Corporation announced today that the U.S. Food and Drug Administration has accepted for review Dynavax's responses to the Complete Response Letter issued by the FDA in November 2016 ...

Dynavax to Present at the 2017 RBC Capital Markets Global Healthcare Conference

2/16/2017 11:00 am

[Marketwired] - Dynavax Technologies Corporation announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference ...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dynavax Technologies Corporation and Encourages Investors with Losses to Contact the Firm

1/14/2017 02:02 am

[Accesswire] - IRVINE, CA / ACCESSWIRE / January 13, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Dynavax Technologies Corporation ("Dynavax" or the "Company") ...